182 related articles for article (PubMed ID: 34283647)
1. Dosimetric feasibility of stereotactic irradiation of primary prostate cancer at 5x9 Gy with a method of urethral sparing.
Benhmida S; Beneux A; Udrescu C; Rouviere O; Horn S; Enachescu C; Lapierre A; Chapet O
Br J Radiol; 2021 Nov; 94(1127):20210142. PubMed ID: 34283647
[TBL] [Abstract][Full Text] [Related]
2. Volumetric-modulated arc stereotactic body radiotherapy for prostate cancer: dosimetric impact of an increased near-maximum target dose and of a rectal spacer.
Ruggieri R; Naccarato S; Stavrev P; Stavreva N; Fersino S; Giaj Levra N; Mazzola R; Mancosu P; Scorsetti M; Alongi F
Br J Radiol; 2015 Oct; 88(1054):20140736. PubMed ID: 26235142
[TBL] [Abstract][Full Text] [Related]
3. Urethra-sparing stereotactic body radiotherapy for prostate cancer: how much can the rectal wall dose be reduced with or without an endorectal balloon?
Dubouloz A; Rouzaud M; Tsvang L; Verbakel W; Björkqvist M; Linthout N; Lencart J; Pérez-Moreno JM; Ozen Z; Escude L; Zilli T; Miralbell R
Radiat Oncol; 2018 Jun; 13(1):114. PubMed ID: 29921291
[TBL] [Abstract][Full Text] [Related]
4. Dosimetric feasibility of neurovascular bundle-sparing stereotactic body radiotherapy with periprostatic hydrogel spacer for localized prostate cancer to preserve erectile function.
Hwang ME; Mayeda M; Shaish H; Elliston CD; Spina CS; Wenske S; Deutsch I
Br J Radiol; 2021 Mar; 94(1119):20200433. PubMed ID: 33586999
[TBL] [Abstract][Full Text] [Related]
5. Urethra-Sparing Stereotactic Body Radiation Therapy for Prostate Cancer: Quality Assurance of a Randomized Phase 2 Trial.
Jaccard M; Zilli T; Dubouloz A; Escude L; Jorcano S; Linthout N; Bral S; Verbakel W; Bruynzeel A; Björkqvist M; Minn H; Tsvang L; Symon Z; Lencart J; Oliveira A; Ozen Z; Abacioglu U; Pérez-Moreno JM; Rubio C; Rouzaud M; Miralbell R
Int J Radiat Oncol Biol Phys; 2020 Nov; 108(4):1047-1054. PubMed ID: 32535161
[TBL] [Abstract][Full Text] [Related]
6. Dosimetric implications of an injection of hyaluronic acid for preserving the rectal wall in prostate stereotactic body radiation therapy.
Chapet O; Udrescu C; Tanguy R; Ruffion A; Fenoglietto P; Sotton MP; Devonec M; Colombel M; Jalade P; Azria D
Int J Radiat Oncol Biol Phys; 2014 Feb; 88(2):425-32. PubMed ID: 24411613
[TBL] [Abstract][Full Text] [Related]
7. Dominant intraprostatic lesion boosting in sexual-sparing radiotherapy of prostate cancer: A planning feasibility study.
Ciabatti S; Ntreta M; Buwenge M; Gaudiano C; Sessagesimi E; Romani F; Angelini AL; Cammelli S; Macchia G; Deodato F; Zamagni A; Golfieri R; Morganti AG; Cilla S
Med Dosim; 2019 Winter; 44(4):356-364. PubMed ID: 30955990
[TBL] [Abstract][Full Text] [Related]
8. Assessment of Monte Carlo algorithm for compliance with RTOG 0915 dosimetric criteria in peripheral lung cancer patients treated with stereotactic body radiotherapy.
Pokhrel D; Sood S; Badkul R; Jiang H; McClinton C; Lominska C; Kumar P; Wang F
J Appl Clin Med Phys; 2016 May; 17(3):277-293. PubMed ID: 27167284
[TBL] [Abstract][Full Text] [Related]
9. Target miss using PTV-based IMRT compared to robust optimization via coverage probability concept in prostate cancer.
Outaggarts Z; Wegener D; Berger B; Zips D; Paulsen F; Bleif M; Thorwarth D; Alber M; Dohm O; Müller AC
Acta Oncol; 2020 Aug; 59(8):911-917. PubMed ID: 32436467
[No Abstract] [Full Text] [Related]
10. Potential interest of developing an integrated boost dose escalation for stereotactic irradiation of primary prostate cancer.
Udrescu C; Rouvière O; Enachescu C; Sotton MP; Bouffard-Vercelli J; Jalade P; Chapet O
Phys Med; 2014 May; 30(3):320-5. PubMed ID: 24169295
[TBL] [Abstract][Full Text] [Related]
11. A treatment planning study comparing IMRT techniques and cyber knife for stereotactic body radiotherapy of low-risk prostate carcinoma.
Scobioala S; Kittel C; Elsayad K; Kroeger K; Oertel M; Samhouri L; Haverkamp U; Eich HT
Radiat Oncol; 2019 Aug; 14(1):143. PubMed ID: 31399115
[TBL] [Abstract][Full Text] [Related]
12. Neurovascular bundle-sparing radiotherapy for prostate cancer using MRI-CT registration: A dosimetric feasibility study.
Cassidy RJ; Yang X; Liu T; Thomas M; Nour SG; Jani AB
Med Dosim; 2016 Winter; 41(4):339-343. PubMed ID: 27745996
[TBL] [Abstract][Full Text] [Related]
13. Stereotactic IMRT for prostate cancer: dosimetric impact of multileaf collimator leaf width in the treatment of prostate cancer with IMRT.
Wang L; Movsas B; Jacob R; Fourkal E; Chen L; Price R; Feigenberg S; Konski A; Pollack A; Ma C
J Appl Clin Med Phys; 2004; 5(2):29-41. PubMed ID: 15738911
[TBL] [Abstract][Full Text] [Related]
14. Dosimetric benefits of hemigland stereotactic body radiotherapy for prostate cancer: implications for focal therapy.
Kishan AU; Park SJ; King CR; Roberts K; Kupelian PA; Steinberg ML; Kamrava M
Br J Radiol; 2015; 88(1056):20150658. PubMed ID: 26463234
[TBL] [Abstract][Full Text] [Related]
15. Dosimetric and radiobiological consequences of computed tomography-guided adaptive strategies for intensity modulated radiation therapy of the prostate.
Battista JJ; Johnson C; Turnbull D; Kempe J; Bzdusek K; Van Dyk J; Bauman G
Int J Radiat Oncol Biol Phys; 2013 Dec; 87(5):874-80. PubMed ID: 23978708
[TBL] [Abstract][Full Text] [Related]
16. Dosimetric predictors for genitourinary toxicity in MR-guided stereotactic body radiation therapy (SBRT): Substructure with fraction-wise analysis.
Pham J; Neilsen BK; Liu H; Cao M; Yang Y; Sheng K; Ma TM; Kishan AU; Ruan D
Med Phys; 2024 Jan; 51(1):612-621. PubMed ID: 38055353
[TBL] [Abstract][Full Text] [Related]
17. Dosimetry analyses comparing high-dose-rate brachytherapy, administered as monotherapy for localized prostate cancer, with stereotactic body radiation therapy simulated using CyberKnife.
Fukuda S; Seo Y; Shiomi H; Yamada Y; Ogata T; Morimoto M; Konishi K; Yoshioka Y; Ogawa K
J Radiat Res; 2014 Nov; 55(6):1114-21. PubMed ID: 24957754
[TBL] [Abstract][Full Text] [Related]
18. Prostate seed implantation using 3D-computer assisted intraoperative planning vs. a standard look-up nomogram: Improved target conformality with reduction in urethral and rectal wall dose.
Raben A; Chen H; Grebler A; Geltzeiler J; Geltzeiler M; Keselman I; Litvin S; Sim S; Hanlon A; Yang J
Int J Radiat Oncol Biol Phys; 2004 Dec; 60(5):1631-8. PubMed ID: 15590195
[TBL] [Abstract][Full Text] [Related]
19. Functional imaging guided stereotactic ablative body radiotherapy (SABR) with focal dose escalation and bladder trigone sparing for intermediate and high-risk prostate cancer: study protocol for phase II safo trial.
Zapatero A; Castro P; Roch M; Carnero PR; Carroceda S; Rosciupchin AES; Hernández SH; Cogorno L; Iturriaga AG; García DB
Radiat Oncol; 2024 May; 19(1):54. PubMed ID: 38702761
[TBL] [Abstract][Full Text] [Related]
20. Comparing photon and proton-based hypofractioned SBRT for prostate cancer accounting for robustness and realistic treatment deliverability.
Goddard LC; Brodin NP; Bodner WR; Garg MK; Tomé WA
Br J Radiol; 2018 May; 91(1085):20180010. PubMed ID: 29436852
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
